n.a. (ELN)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Div & Yield N.A. (N.A)
Elan Board Unanimously Accepts McKenna Long Report

Elan Board Unanimously Accepts McKenna Long Report

Elan Corporation, plc (“Elan”) (NYSE: ELN) announced that at yesterday’s meeting of the Elan Board of Directors, the Board unanimously accepted a report prepared by the United States law firm of McKenna Long...

The MS Active Wellness Fitness Program Can Be Modified As Necessary So Almost All People With MS Can Participate In The Workouts, Regardless Of Current Ability Or Fitness Level. (Photo: Business Wire)

Biogen Idec and Elan Corporation, plc today announced the launch of MS Active Wellness, a new resource available through MS ActiveSource, which provides tools to help people with multiple sclerosis (MS) achieve...

Elan Statement Regarding Shareholder Call

Elan Corporation, plc ("Elan") (NYSE:ELN) today issued the following statement in response to a public conference call organized by an investor who has proposed directors for Elan’s Board: “As...

Elan Corporation Plc Announces Commencement Of Asset Sale Offer To Purchase Up To $186,000,000 Of 8 7/8% Senior Fixed Rate Notes Due 2013 And Floating Rate Notes Due 2013

Elan Corporation Plc Announces Commencement Of Asset Sale Offer To Purchase Up To $186,000,000 Of 8 7/8% Senior Fixed Rate Notes Due 2013 And Floating Rate Notes Due 2013

Elan Corporation, plc (“Elan”) (NYSE: ELN) announced today that Elan’s wholly-owned subsidiaries, Elan Finance public limited company (“Elan Finance”) and Elan Finance Corp.

Preliminary Data In Support Of Investigational Anti-JCV Antibody Assay Published In The Annals Of Neurology

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced data has been published in the Annals of Neurology on an investigational, two-step assay to detect anti-JC virus (JCV)...

Charts of the Week: Supervalu, Elan, Motorola

Here is a technical analysis of how these stocks may fare.

10 Alzheimer's Disease Treatment Stocks

10 Alzheimer's Disease Treatment Stocks

Despite recent setbacks, investors are still searching for a company to unlock a treatment for Alzheimer's disease.

Elan Corporation, Plc Announces Redemption Of Its Senior Floating Rate Notes Due 2011

Elan Corporation, plc (“Elan”) (NYSE: ELN) announced today that it will redeem all of the outstanding Senior Floating Rate Notes due 2011 (the “Notes”) of its wholly owned subsidiaries, Elan Finance...

Elan Corporation Plc Announces Pricing Of 2016 Senior Notes

Elan Corporation, plc ("Elan") (NYSE: ELN) today announced the pricing of the offering of US$200 million aggregate principal amount of 8.

Elan Corporation Plc Announces Intent To Offer US$200m In Aggregate Principal Amount Of 8.75% Senior Notes Due 2016

Elan Corporation, plc (“Elan”) (NYSE: ELN) today announced that its wholly-owned subsidiaries, Elan Finance public limited company (“Elan Finance”) and Elan Finance Corp.

Elan And Transition Therapeutics Announce Topline Summary Results Of Phase 2 Study And Plans For Phase 3 For ELND005 (Scyllo-inositol )

Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics, Inc (TSX: TTH, NASDAQ:TTHI) today announced the results of a Phase 2 placebo-controlled study in 351 patients with mild to moderate Alzheimer’s...

Elan Provides Update On Initiatives To Further Enhance Balance Sheet And Operating Performance

Elan Corporation, plc (“Elan” or the “Company”) (NYSE: ELN) today announced continued progress on the Company’s ongoing efforts to maximize financial performance and strength, and to position its...

Elan Reports Second Quarter And First Half 2010 Financial Results

Elan Corporation, plc today reported its second quarter and first half 2010 financial results.

Elan Corporation, Plc Reaches Agreement In Principle For Settlement Of Investigation Of Past Zonegran Sales And Marketing Activities

Elan Corporation, Plc Reaches Agreement In Principle For Settlement Of Investigation Of Past Zonegran Sales And Marketing Activities

Elan Corporation, plc (NYSE: ELN) today announced that it has reached an agreement in principle with the United States Attorney’s Office for the District of Massachusetts with respect to the previously disclosed U.

Elan Announces Webcast Of Second Quarter 2010 Financial Results

Elan Announces Webcast Of Second Quarter 2010 Financial Results

Elan Corporation, plc (NYSE:ELN) announced today that it will host a conference call on Thursday, July 22, at 8:30 a.

Eliseo O. Salinas, MD, MSc Joins Elan As Executive Vice President And Chief Medical Officer

Eliseo O. Salinas, MD, MSc Joins Elan As Executive Vice President And Chief Medical Officer

Elan Corporation, plc (NYSE: ELN) today announced that Eliseo Oreste Salinas, MD, MSc, has joined the company as Executive Vice President and Chief Medical Officer effective immediately, with responsibility for leading...

Elan To Present At The Goldman Sachs 31st Annual Healthcare Conference

Elan Corporation, plc (NYSE: ELN) today announced that it will present at the Goldman Sachs 31 st Annual Healthcare Conference on Tuesday, June 15, 2010, at 2:30 p.

Elan Corporation, Plc Board Announces CEO Agreement

As a key part of its commitment to excellence in corporate governance and prudent executive succession management, Elan Corporation, plc announced today that its Board and Mr.

Elan To Present At The Jefferies Global Life Sciences Conference

Elan Corporation, plc (NYSE: ELN) today announced that it will present at the Jefferies Global Life Sciences Conference on Tuesday, June 8, 2010, at 3:30 p.

Elan Reports First Quarter 2010 Financial Results

Elan Corporation, plc, today reported its first quarter 2010 financial results.

Elan Announces Exploration Of EDT Separation And Board Changes

Elan Corporation, plc has decided to explore the possibility of a separation of its Elan Drug Technologies (EDT) business.

Large Body Of Data On TYSABRI® To Be Presented At Annual Meeting Of The American Academy Of Neurology

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced 15 company-sponsored platform and poster presentations at the American Academy of Neurology’s (AAN) 62 nd Annual Meeting...

Elan Announces Webcast Of First Quarter 2010 Financial Results

Elan Corporation, plc (NYSE: ELN) announced today that it will host a conference call on Wednesday, April 21, at 8:30 a.

Elan Announces Filing Of Annual Report For Year Ended December 31, 2009

Elan Corporation, plc (NYSE: ELN) today announced the publication and filing of its Annual Report for the fiscal year ended December 31, 2009.

Biogen Idec And Elan Enroll First Patient In Large, Well-Controlled Head-to-Head Study Of Multiple Sclerosis Treatments

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced enrollment of the first patient in a global Phase IIIb, randomized, rater-blinded, active-controlled study designed to evaluate...

Elan To Present At The Barclays Capital 2010 Global Healthcare Conference

Elan Corporation, plc (NYSE: ELN) today announced that it will present at the Barclays Capital 2010 Global Healthcare Conference on Tuesday, March 23, 2010, at 9:00 a.

Elan To Present At The Cowen And Company Healthcare Conference

Elan Corporation, plc (NYSE: ELN) today announced that it will present at the Cowen and Company Healthcare Conference on Wednesday, March 10, 2010, at 8:45 a.

Medivation: Biotech Stock Mailbag

Medivation's (MDVN) Alzheimer's drug, Dimebon, failed an important drug trial. Hard lessons were learned, as explained in this bonus Mailbag.

Medivation Alzheimer's Drug Fails Pivotal Study

Medivation Alzheimer's Drug Fails Pivotal Study

Medivation's (MDVN) Alzheimer's drug failed a pivotal study. Dimebon was unable to improve cognitive function over placebo in a phase III study.

Neuroimaging Technique Supports Reduction In Amyloid-Beta In Brains Of Patients Suffering From Alzheimer’s Disease Treated With Bapineuzumab

Neuroimaging Technique Supports Reduction In Amyloid-Beta In Brains Of Patients Suffering From Alzheimer’s Disease Treated With Bapineuzumab

Elan Corporation, plc (NYSE: ELN) today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer’s disease patients as measured using a...